All In Biotech

Drug Trial Radar · NCT00648596

A Study to Evaluate Self-esteem and Relationships in Males With Erectile Dysfuntion

An International, Multicentre, Randomized, Parallel Group, Double Blind, Placebo Controlled, Flexible Dose Study to Evaluate Self-esteem and Relationships in Males With Erectile Dysfunction Treated With Sildenafil Citrate

Last checked: Nov 19, 2026Latest source record: Feb 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 780 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

780

Actual

Start

May 2003

Primary completion

Not stated

Study completion May 2004

Sponsor

Sponsor type
Industry
First posted
Apr 1, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine the improvement in the self-esteem domain score of the Self-Esteem/Overall Relationship (SEAR) questionnaire and the improvement in erectile function (obtained from the Erectile Function \[EF\] domain of the International Index of Erectile Function \[IIEF\]). Furthermore, to determine if the improvement obtained in self-esteem was related to the main erectile dysfunction (ED) co-morbidities type and/or number.

Conditions

  • Erectile Dysfunction

Interventions

  • sildenafilDrug

    sildenafil 50 mg tablet by mouth 1 hour before sexual activity for 12 weeks; the dose could be increased to 100 mg or decreased to 25 mg.

  • placeboDrug

    placebo tablet by mouth 1 hour before sexual activity for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in the Self-esteem domain of the SEAR questionnaireTime frame: Week 12

Locations

66 sites in 8 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Oulu, Finland

  • Pfizer Investigational Site

    Tampere, Finland

  • Pfizer Investigational Site

    Turku, Finland

  • Pfizer Investigational Site

    Clermont-Ferrand, France

  • Pfizer Investigational Site

    LE Kremlin Bicentre, France

  • Pfizer Investigational Site

    Lyon, France

  • Pfizer Investigational Site

    Marseille, France

  • Pfizer Investigational Site

    Neuilly-sur-Seine, France

  • Pfizer Investigational Site

    Nice, France

  • Pfizer Investigational Site

    Nîmes, France

  • Pfizer Investigational Site

    Toulouse, France

  • Pfizer Investigational Site

    Bari, Italy

  • Pfizer Investigational Site

    Catania, Italy

  • Pfizer Investigational Site

    Gallarate (VA), Italy

  • Pfizer Investigational Site

    Modena, Italy

  • Pfizer Investigational Site

    Padova, Italy

  • Pfizer Investigational Site

    Roma, Italy

  • Pfizer Investigational Site

    Siena, Italy

  • Pfizer Investigational Site

    Torino, Italy

  • Pfizer Investigational Site

    Krakow, Poland

  • Pfizer Investigational Site

    Lodz, Poland

  • Pfizer Investigational Site

    Lublin, Poland

  • Pfizer Investigational Site

    Olsztyn, Poland

  • Pfizer Investigational Site

    Szczecin, Poland

  • Pfizer Investigational Site

    Warsaw, Poland

  • Pfizer Investigational Site

    Barnaul, Russia

  • Pfizer Investigational Site

    Moscow, Russia

  • Pfizer Investigational Site

    Moscow, Russia

  • Pfizer Investigational Site

    Moscow, Russia

  • Pfizer Investigational Site

    Moscow, Russia

  • Pfizer Investigational Site

    Moscow, Russia

  • Pfizer Investigational Site

    Moscow, Russia

  • Pfizer Investigational Site

    Moscow, Russia

  • Pfizer Investigational Site

    Moscow, Russia

  • Pfizer Investigational Site

    Nizhny Novgorod, Russia

  • Pfizer Investigational Site

    Novosibirsk, Russia

  • Pfizer Investigational Site

    Novosibirsk, Russia

  • Pfizer Investigational Site

    Rostov-on-Don, Russia

  • Pfizer Investigational Site

    Saint Petersburg, Russia

  • Pfizer Investigational Site

    Saint Petersburg, Russia

Showing 40 of 66 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.